Details for: NIBAN1
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 50.18rCSI 72%PRS 46.19
-
CSI 17.3rCSI 50.08%PRS 57.83
-
CSI 16.72rCSI 41.38%PRS 54.31
-
CSI 14.85rCSI 47.81%PRS 54.47
-
CSI 13.47rCSI 9.07%PRS 68.81
-
CSI 10.66rCSI 12.77%PRS 73.91
-
CSI 10.03rCSI 52.7%PRS 62.04
-
CSI 9.21rCSI 28.81%PRS 42.47
-
CSI 9.2rCSI 13.89%PRS 59.53
-
CSI 8.62rCSI 6.48%PRS 61.06
-
CSI 8.19rCSI 20.72%PRS 64.52
-
CSI 8.08rCSI 23.97%PRS 66.26
-
CSI 7.39rCSI 46.13%PRS 47.95
-
CSI 6.98rCSI 8.95%PRS 61.01
-
CSI 6.76rCSI 21.91%PRS 57.54
-
CSI 6.7rCSI 8.53%PRS 62.47
-
CSI 6.14rCSI 15.88%PRS 83.34
-
CSI 5.95rCSI 5.74%PRS 46.67
-
CSI 5.6rCSI 4.02%PRS 70.22
-
CSI 5.42rCSI 6.81%PRS 68.67
-
CSI 5.39rCSI 5.19%PRS 56.45
-
CSI 5.14rCSI 12.26%PRS 63.35
-
CSI 5.12rCSI 5.34%PRS 56.47
-
CSI 5.09rCSI 7.78%PRS 56.64
-
CSI 4.88rCSI 6.67%PRS 61.73
-
CSI 4.75rCSI 10.36%PRS 71.9
-
CSI 4.58rCSI 5.37%PRS 72.65
-
CSI 4.4rCSI 14.58%PRS 59.12
-
CSI 4.22rCSI 12.46%PRS 54.3
-
CSI 4.21rCSI 5.41%PRS 49.38
-
CSI 4.21rCSI 3.4%PRS 66.26
-
CSI 4.17rCSI 11.48%PRS 51.83
-
CSI 4.12rCSI 6.05%PRS 67.69
-
CSI 4.08rCSI 16.3%PRS 73.84
-
CSI 4.05rCSI 6.94%PRS 65.43
-
CSI 3.97rCSI 3.67%PRS 76.08
-
CSI 3.84rCSI 5.44%PRS 62.44
-
CSI 3.77rCSI 2.23%PRS 73.14
-
CSI 3.65rCSI 4.36%PRS 76.26
-
CSI 3.56rCSI 19.91%PRS 64.3
-
CSI 3.51rCSI 7.84%PRS 63.65
-
CSI 3.45rCSI 5.59%PRS 53.37
-
CSI 3.44rCSI 4.28%PRS 66.76
-
CSI 3.31rCSI 56%PRS 80.61
-
CSI 3.26rCSI 2.53%PRS 74.06
-
CSI 3.21rCSI 5.49%PRS 80.57
-
CSI 3.13rCSI 2.32%PRS 48.79
-
CSI 3.06rCSI 45.99%PRS 75.17
-
CSI 2.98rCSI 8.47%PRS 54.26
-
CSI 2.95rCSI 4.27%PRS 72.13
-
CSI 2.88rCSI 3.24%PRS 72.75
-
CSI 2.85rCSI 2.63%PRS 57.21
-
CSI 2.85rCSI 3.73%PRS 69.58
-
CSI 2.74rCSI 6.51%PRS 60.67
-
CSI 2.74rCSI 2.13%PRS 57.51
-
CSI 2.67rCSI 12.34%PRS 75.75
-
CSI 2.65rCSI 3.42%PRS 39.68
-
CSI 2.63rCSI 5.44%PRS 58.99
-
CSI 2.63rCSI 2.59%PRS 72.11
-
CSI 2.59rCSI 2.71%PRS 80.36
-
CSI 2.59rCSI 6.92%PRS 47.6
-
CSI 2.55rCSI 1.78%PRS 58.91
-
CSI 2.53rCSI 58.98%PRS 77.05
-
CSI 2.49rCSI 3.96%PRS 48.53
-
CSI 2.42rCSI 4.57%PRS 66.63
-
CSI 2.41rCSI 5%PRS 53.36
-
CSI 2.27rCSI 2.23%PRS 79.31
-
CSI 2.19rCSI 8.19%PRS 48.29
-
CSI 2.18rCSI 5.67%PRS 55.45
-
CSI 2.17rCSI 4.88%PRS 74.28
-
CSI 2.16rCSI 3.17%PRS 60.16
-
CSI 2.16rCSI 5.67%PRS 76.07
-
CSI 2.12rCSI 1.76%PRS 55.12
-
CSI 2.11rCSI 11.34%PRS 69.58
-
CSI 2.1rCSI 1.91%PRS 70.58
-
CSI 2.09rCSI 2.14%PRS 72.07
-
CSI 2.07rCSI 2.22%PRS 54.98
-
CSI 2.07rCSI 1.79%PRS 60.9
-
CSI 2.05rCSI 6.11%PRS 75.39
-
CSI 2.05rCSI 3.25%PRS 67.26
-
CSI 2.04rCSI 9.57%PRS 72.61
-
CSI 2.04rCSI 2.98%PRS 53.14
-
CSI 2rCSI 3.79%PRS 75.82
-
CSI 2rCSI 2.67%PRS 56.78
-
CSI 1.98rCSI 5.73%PRS 70.27
-
CSI 1.96rCSI 2.27%PRS 64.63
-
CSI 1.92rCSI 6.02%PRS 40.02
-
CSI 1.91rCSI 1.44%PRS 69.75
-
CSI 1.91rCSI 7.21%PRS 39.37
-
CSI 1.84rCSI 10.34%PRS 81.69
-
CSI 1.77rCSI 3.12%PRS 64.46
-
CSI 1.73rCSI 6.97%PRS 54.58
-
CSI 1.73rCSI 2%PRS 46.13
-
CSI 1.72rCSI 3.78%PRS 60.11
-
CSI 1.71rCSI 3.24%PRS 86.27
-
CSI 1.7rCSI 4.88%PRS 75.65
-
CSI 1.68rCSI 5.38%PRS 53.19
-
CSI 1.66rCSI 4%PRS 64.1
-
CSI 1.66rCSI 1.39%PRS 60.91
-
CSI 1.66rCSI 2.36%PRS 58.61
-
CSI 0.2rCSI 2.0%PRS 69.8%
-
CSI 0.3rCSI 1.3%PRS 68.7%
-
CSI 0.3rCSI 1.9%PRS 66.5%
-
CSI 0.5rCSI 11.0%PRS 58.0%
-
CSI 0.5rCSI 2.9%PRS 65.9%
-
CSI 0.5rCSI 2.2%PRS 70.0%
-
CSI 0.6rCSI 4.4%PRS 47.7%
-
CSI 0.7rCSI 4.6%PRS 73.0%
-
CSI 0.7rCSI 6.7%PRS 77.6%
-
CSI 0.7rCSI 1.3%PRS 32.9%
-
CSI 0.8rCSI 4.5%PRS 74.4%
-
CSI 0.8rCSI 5.9%PRS 66.1%
-
CSI 0.8rCSI 0.8%PRS 49.7%
-
CSI 0.9rCSI 9.3%PRS 72.7%
-
CSI 0.9rCSI 0.8%PRS 64.6%
-
CSI 1.0rCSI 7.9%PRS 49.2%
-
CSI 1.0rCSI 1.6%PRS 72.5%
-
CSI 1.1rCSI 5.4%PRS 83.5%
-
CSI 1.1rCSI 1.0%PRS 52.9%
-
CSI 1.1rCSI 0.8%PRS 56.0%
-
CSI 1.1rCSI 1.1%PRS 61.6%
-
CSI 1.1rCSI 3.0%PRS 64.8%
-
CSI 1.1rCSI 2.2%PRS 83.2%
-
CSI 1.2rCSI 1.7%PRS 76.2%
-
CSI 1.2rCSI 4.2%PRS 69.8%
-
CSI 1.2rCSI 5.9%PRS 55.6%
-
CSI 1.3rCSI 2.6%PRS 75.6%
-
CSI 1.3rCSI 2.3%PRS 72.2%
-
CSI 1.3rCSI 1.6%PRS 58.2%
-
CSI 1.3rCSI 1.9%PRS 65.9%
-
CSI 1.3rCSI 2.3%PRS 46.3%
-
CSI 1.4rCSI 1.1%PRS 78.1%
-
CSI 1.4rCSI 2.1%PRS 64.7%
-
CSI 1.4rCSI 2.5%PRS 79.6%
-
CSI 1.4rCSI 1.7%PRS 64.6%
-
CSI 1.4rCSI 3.0%PRS 74.8%
-
CSI 1.4rCSI 1.9%PRS 62.0%
-
CSI 1.5rCSI 4.1%PRS 70.2%
-
CSI 1.5rCSI 4.0%PRS 73.9%
-
CSI 1.5rCSI 2.3%PRS 65.4%
-
CSI 1.6rCSI 3.7%PRS 65.0%
-
CSI 1.6rCSI 2.6%PRS 61.4%
-
CSI 1.6rCSI 7.6%PRS 55.0%
-
CSI 1.6rCSI 1.3%PRS 57.3%
-
CSI 1.7rCSI 2.4%PRS 58.6%
-
CSI 1.7rCSI 1.4%PRS 60.9%
-
CSI 1.7rCSI 4.0%PRS 64.1%
-
CSI 1.7rCSI 5.4%PRS 53.2%
-
CSI 1.7rCSI 4.9%PRS 75.7%
-
CSI 1.7rCSI 3.2%PRS 86.3%
-
CSI 1.7rCSI 3.8%PRS 60.1%
-
CSI 1.7rCSI 2.0%PRS 46.1%
-
CSI 1.7rCSI 7.0%PRS 54.6%
-
CSI 1.8rCSI 3.1%PRS 64.5%
-
CSI 1.8rCSI 10.3%PRS 81.7%
-
CSI 1.9rCSI 7.2%PRS 39.4%
-
CSI 1.9rCSI 1.4%PRS 69.8%
-
CSI 1.9rCSI 6.0%PRS 40.0%
-
CSI 2.0rCSI 2.3%PRS 64.6%
-
CSI 2.0rCSI 5.7%PRS 70.3%
-
CSI 2.0rCSI 2.7%PRS 56.8%
-
CSI 2.0rCSI 3.8%PRS 75.8%
-
CSI 2.0rCSI 3.0%PRS 53.1%
-
CSI 2.0rCSI 9.6%PRS 72.6%
-
CSI 2.1rCSI 3.3%PRS 67.3%
-
CSI 2.1rCSI 6.1%PRS 75.4%
-
CSI 2.1rCSI 1.8%PRS 60.9%
-
CSI 2.1rCSI 2.2%PRS 55.0%
-
CSI 2.1rCSI 2.1%PRS 72.1%
-
CSI 2.1rCSI 1.9%PRS 70.6%
-
CSI 2.1rCSI 11.3%PRS 69.6%
-
CSI 2.1rCSI 1.8%PRS 55.1%
-
CSI 2.2rCSI 5.7%PRS 76.1%
-
CSI 2.2rCSI 3.2%PRS 60.2%
-
CSI 2.2rCSI 4.9%PRS 74.3%
-
CSI 2.2rCSI 5.7%PRS 55.5%
-
CSI 2.2rCSI 8.2%PRS 48.3%
-
CSI 2.3rCSI 2.2%PRS 79.3%
-
CSI 2.4rCSI 5.0%PRS 53.4%
-
CSI 2.4rCSI 4.6%PRS 66.6%
-
CSI 2.5rCSI 4.0%PRS 48.5%
-
CSI 2.5rCSI 59.0%PRS 77.1%
-
CSI 2.6rCSI 1.8%PRS 58.9%
-
CSI 2.6rCSI 6.9%PRS 47.6%
-
CSI 2.6rCSI 2.7%PRS 80.4%
-
CSI 2.6rCSI 2.6%PRS 72.1%
-
CSI 2.6rCSI 5.4%PRS 59.0%
-
CSI 2.7rCSI 3.4%PRS 39.7%
-
CSI 2.7rCSI 12.3%PRS 75.8%
-
CSI 2.7rCSI 2.1%PRS 57.5%
-
CSI 2.7rCSI 6.5%PRS 60.7%
-
CSI 2.9rCSI 3.7%PRS 69.6%
-
CSI 2.9rCSI 2.6%PRS 57.2%
-
CSI 2.9rCSI 3.2%PRS 72.8%
-
CSI 3.0rCSI 4.3%PRS 72.1%
-
CSI 3.0rCSI 8.5%PRS 54.3%
-
CSI 3.1rCSI 46.0%PRS 75.2%
-
CSI 3.1rCSI 2.3%PRS 48.8%
-
CSI 3.2rCSI 5.5%PRS 80.6%
-
CSI 3.3rCSI 2.5%PRS 74.1%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Comma-separated if multiple.
Comma-separated if multiple.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.
Genular Protein ID: 1883634849
Symbol: NIBA1_HUMAN
Name: Cell growth-inhibiting gene 39 protein
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11011112
Title: A novel gene 'Niban' upregulated in renal carcinogenesis: cloning by the cDNA-amplified fragment length polymorphism approach.
PubMed ID: 11011112
PubMed ID: 11318611
Title: Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus.
PubMed ID: 11318611
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 16710414
Title: The DNA sequence and biological annotation of human chromosome 1.
PubMed ID: 16710414
DOI: 10.1038/nature04727
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 16949643
Title: A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis.
PubMed ID: 16949643
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25807930
Title: Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.
PubMed ID: 25807930
Sequence Information:
- Length: 928
- Mass: 103135
- Checksum: 93717F41336488FE
- Sequence:
MGGSASSQLD EGKCAYIRGK TEAAIKNFSP YYSRQYSVAF CNHVRTEVEQ QRDLTSQFLK TKPPLAPGTI LYEAELSQFS EDIKKWKERY VVVKNDYAVE SYENKEAYQR GAAPKCRILP AGGKVLTSED EYNLLSDRHF PDPLASSEKE NTQPFVVLPK EFPVYLWQPF FRHGYFCFHE AADQKRFSAL LSDCVRHLNH DYMKQMTFEA QAFLEAVQFF RQEKGHYGSW EMITGDEIQI LSNLVMEELL PTLQTDLLPK MKGKKNDRKR TWLGLLEEAY TLVQHQVSEG LSALKEECRA LTKGLEGTIR SDMDQIVNSK NYLIGKIKAM VAQPAEKSCL ESVQPFLASI LEELMGPVSS GFSEVRVLFE KEVNEVSQNF QTTKDSVQLK EHLDRLMNLP LHSVKMEPCY TKVNLLHERL QDLKSRFRFP HIDLVVQRTQ NYMQELMENA VFTFEQLLSP HLQGEASKTA VAIEKVKLRV LKQYDYDSST IRKKIFQEAL VQITLPTVQK ALASTCKPEL QKYEQFIFAD HTNMIHVENV YEEILHQILL DETLKVIKEA AILKKHNLFE DNMALPSESV SSLTDLKPPT GSNQASPARR ASAILPGVLG SETLSNEVFQ ESEEEKQPEV PSSLAKGESL SLPGPSPPPD GTEQVIISRV DDPVVNPVAT EDTAGLPGTC SSELEFGGTL EDEEPAQEEP EPITASGSLK ALRKLLTASV EVPVDSAPVM EEDTNGESHV PQENEEEEEK EPSQAAAIHP DNCEESEVSE REAQPPCPEA HGEELGGFPE VGSPASPPAS GGLTEEPLGP MEGELPGEAC TLTAHEGRGG KCTEEGDASQ QEGCTLGSDP ICLSESQVSE EQEEMGGQSS AAQATASVNA EEIKVARIHE CQWVVEDAPN PDVLLSHKDD VKEGEGGQES FPELPSEE